ArticleBMC endocrine disorders2026
Associations between DXA-derived parameters of body composition and bone mass density in patients with T2DM and metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease(MASLD) is associated with the deterioration of bone mass density(BMD), but the independent contributions of soft tissue parameters of body composition are not fully understood. We aimed to evaluate the relationship between the degree of liver steatosis, as assessed by vibration-controlled transient elastography(FibroScan
methods156 patients, 95 females and 61 males, aged 33-78 years, treated for T2DM and MASLD with oral antidiabetic medication, were included in this cross-sectional study. Subgroup analyses were conducted by sex, age, BMI, lean mass index, and the extent of fibrosis. Multiple linear regression models were fitted with BMD indices as the dependent variable and the Controlled Attenuation Parameter(CAP) as a measure of liver steatosis, serving as the independent variable. The models were adjusted for age, sex, HOMA-IR, BMI, lean mass index, and android fat mass%. Accordingly, ROC curves with T-score(Z-score)=-1.0 were plotted as a classifier of bone mass deterioration.
resultsThe total BMD and CAP were positively correlated in the entire group(r = 0.21,p = 0.001) and in the female group(r = 0.29,p = 0.004), but not in the male group(r = 0.08,p = 0.51). The association maintained significance after adjustment for total body fat%(r = 0.23,p = 0.003), AGR(r = 0.22,p = 0.005), lean mass index(r = 0.19,p = 0.02) and osteocalcin(r = 0.16,p = 0.04) but not for BMI(r = 0.13,p = 0.09). The AUC in the female group for total BMD in the model calculated from CAP and android fat mass% and adjusted for age, was: ROC = 0.746(95%CI 0.62-0.88).
conclusionsOur results demonstrate existing discrepancies in the association between BMD and MASLD across sex-, age-, BMI-, lean mass index-, and fibrosis-stratified analyses. CAP and android fat% may have clinical value in predicting osteopenia in patients with MASLD and T2DM. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.